Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis

References

• Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985;230(4729):1054–1057. [Epub 1985 Nov 29]. PubMed PMID: 2997931.
   PubMed Web of Science ®Google Scholar
• Egan ME. Genetics of cystic fibrosis: clinical implications. Clin Chest Med. 2016;37(1):9–16. PubMed PMID: 26857764. DOI:10.1016/j.ccm.2015.11.002
   PubMed Web of Science ®Google Scholar
• Sosnay PR, Raraigh KS, Gibson RL. Molecular genetics of cystic fibrosis transmembrane conductance regulator: genotype and phenotype. Pediatr Clin North Am. 2016;63(4):585–598. PubMed PMID: 27469177. DOI:10.1016/j.pcl.2016.04.002
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–951. PubMed PMID: 14555458.
   PubMed Web of Science ®Google Scholar
• Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360–367. PubMed PMID: 17387214.
   PubMed Web of Science ®Google Scholar
• Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2004;37(5):400–406. PubMed PMID: 15095322.
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNAse on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. 1994;331(10):637–642. PubMed PMID: 7503821.
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–240. Epub 2006 Jan 20. DOI:10.1056/NEJMoa043900
   PubMed Web of Science ®Google Scholar
• Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial Jama 2010;303(17):1707–1715. Epub 2010 May 06. 303/17/1707 [pii]. PubMed PMID: 20442386. DOI:10.1001/jama.2010.563
   PubMed Web of Science ®Google Scholar
• Anstead M, Saiman L, Mayer-Hamblett N, et al. Pulmonary exacerbations in CF patients with early lung disease J Cyst Fibros 2014;13(1):74–79. Epub 2013 Sep 14. PubMed PMID: 24029220. S1569-1993(13)00121-5 [pii]. DOI:10.1016/j.jcf.2013.07.006
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial Jama 2012;307(21):2269–2277. Epub 2012 May 23. PubMed PMID: 22610452. 1158855 [pii]. DOI:10.1001/jama.2012.5214
   PubMed Web of Science ®Google Scholar
• Mayer-Hamblett N, Ratjen F Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy? Lancet Respir Med 2013;1(2):98–99. Epub 2014 Jan 17. PubMed PMID: 24429079. S2213-2600(13)70013-4 [pii]. DOI:10.1016/S2213-2600(13)70013-4
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation Am J Respir Crit Care Med 2010;182(5):627–632. Epub 2010 May 14. PubMed PMID: 20463179. 200909-1421OC [pii]. DOI:10.1164/rccm.200909-1421OC
   PubMed Web of Science ®Google Scholar
• Waters V, Atenafu EG, Salazar JG, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis J Cyst Fibros 2012;11(1):8–13. Epub 2011 Aug 19. PubMed PMID: 21849265. S1569-1993(11)00131-7 [pii]. DOI:10.1016/j.jcf.2011.07.008
   PubMed Web of Science ®Google Scholar
• Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Eur Respir J 2012;40(1):61–66. Epub 2011 Dec 03. PubMed PMID: 22135280. 09031936.00159111 [pii]. DOI:10.1183/09031936.00159111
   PubMed Web of Science ®Google Scholar
• Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):134–9, 9 e1. PubMed PMID: 17643762.
   PubMed Web of Science ®Google Scholar
• Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91–100. PubMed PMID: 12112774.
   PubMed Web of Science ®Google Scholar
• Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146(5):681–687. PubMed PMID: 15870674.
   PubMed Web of Science ®Google Scholar
• Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med. 2005;172(1):99–104. PubMed PMID: 15831839.
   PubMed Web of Science ®Google Scholar
• Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64–72. PubMed PMID: 11796433.
   PubMed Web of Science ®Google Scholar
• Solem CT, Vera-Llonch M, Liu S, et al. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016;14:63. PubMed PMID: 27097977; PMCID: PMC4839094. DOI:10.1186/s12955-016-0465-z
   PubMed Web of Science ®Google Scholar
• Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345–352. PubMed PMID: 11207152.
   PubMed Web of Science ®Google Scholar
• Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2013;48(7):666–673. Epub 2012 Aug 14. DOI:10.1002/ppul.22652
   PubMed Web of Science ®Google Scholar
• Stanojevic S, McDonald A, Waters V, et al. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax. 2016. pii: thoraxjnl-2016-208450. PubMed PMID: 27539619. doi:10.1136/thoraxjnl-2016-208450. [Epub ahead of print].
   Google Scholar
• De Boer KVK, Tullis E, Doucette S, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011;66:680–685.
   PubMed Web of Science ®Google Scholar
• Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol. 1996;143(10):1007–1017. Epub 1996 May 15. PubMed PMID: 8629607.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests Eur Respir J 2005;26(5):948–968. Epub 2005 Nov 03. PubMed PMID: 16264058. 26/5/948 [pii]. DOI:10.1183/09031936.05.00035205
   PubMed Web of Science ®Google Scholar
• Canadian Patient Data Registry Report. Toronto: Cystic fibrosis Canada; 2014.
   Google Scholar
• Kent L, Reix P, Innes JA, et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis J Cyst Fibros 2014;13(2):123–138. Epub 2013 Dec 10. PubMed PMID: 24315208. S1569-1993(13)00155-0 [pii]. DOI:10.1016/j.jcf.2013.09.005
   PubMed Web of Science ®Google Scholar
• Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function Thorax 2010;65(5):379–383. Epub 2010 May 04. PubMed PMID: 20435858. 65/5/379 [pii]. DOI:10.1136/thx.2009.125831
   PubMed Web of Science ®Google Scholar
• Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis Eur Respir J 2011;37(4):806–812. Epub 2010 Aug 10. PubMed PMID: 20693248. 09031936.00072510 [pii]. DOI:10.1183/09031936.00072510
   PubMed Web of Science ®Google Scholar
• Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial Lancet Respir Med 2013;1(8):630–638. Epub 2014 Jan 28. PubMed PMID: 24461666. S2213-2600(13)70182-6 [pii]. DOI:10.1016/S2213-2600(13)70182-6
   PubMed Web of Science ®Google Scholar
• Sonneveld N, Stanojevic S, Amin R, et al. Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations Eur Respir J 2015;46(4):1055–1064. Epub 2015 Jul 15. PubMed PMID: 26160868. 09031936.00211914 [pii]. DOI:10.1183/09031936.00211914
   PubMed Web of Science ®Google Scholar
• Coburn BWP, Caballero JD, Clark ST, et al. Lung microbiota across age and disease stage in cystic fibrosis. Scientific Reports. 2015;5:10241. Epub In Press.
   Web of Science ®Google Scholar
• Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999;28(5):321–328. PubMed PMID: 10536062.
   PubMed Web of Science ®Google Scholar
• Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev. 2016;(1):CD009530. Epub 2016 Jan 23. pub3. PubMed PMID: 26797965. DOI:10.1002/14651858.CD009530
   Google Scholar
• Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial Jama 2011;306(2):163–171. Epub 2011 Jul 14. PubMed PMID: 21750293. 306/2/163 [pii]. DOI:10.1001/jama.2011.954
   PubMed Web of Science ®Google Scholar
• Al-Saleh S, Dell SD, Grasemann H, et al. Sputum induction in routine clinical care of children with cystic fibrosis J Pediatr 2010;157(6):1006–11 e1. Epub 2010 ul 16. PubMed PMID: 20630539. S0022-3476(10)00481-6 [pii]. DOI:10.1016/j.jpeds.2010.06.001
   PubMed Web of Science ®Google Scholar
• Hoppe JE, Towler E, Wagner BD, et al. Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol. 2015;50(7):638–646. Epub 2015 Jan 08. DOI:10.1002/ppul.23150
   PubMed Web of Science ®Google Scholar
• Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis J Cyst Fibros 2012;11(5):433–439. Epub 2012 May 15. PubMed PMID: 22579414. S1569-1993(12)00056-2 [pii]. DOI:10.1016/j.jcf.2012.04.006
   PubMed Web of Science ®Google Scholar
• Goffard A, Lambert V, Salleron J, et al. Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients J Clin Virol 2014;60(2):147–153. Epub 2014 Mar 19. PubMed PMID: 24637203. S1386-6532(14)00069-9 [pii]. DOI:10.1016/j.jcv.2014.02.005
   PubMed Web of Science ®Google Scholar
• De Almeida MB, Zerbinati RM, Tateno AF, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–999. Epub 2010 May 29. DOI:10.3201/eid1606.100063
   PubMed Web of Science ®Google Scholar
• Abman SH, Ogle JW, Butler-Simon N, et al. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113(5):826–830. PubMed PMID: 3183835.
   PubMed Web of Science ®Google Scholar
• Cousin M, Molinari N, Foulongne V, et al. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis. Influenza Other Respir Viruses. 2016;10(2):109–112. Epub 2015 Oct 24. DOI:10.1111/irv.12353
   PubMed Web of Science ®Google Scholar
• De Vrankrijker AM, Wolfs TF, Ciofu O, et al. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol. 2009;81(12):2096–2103. PubMed PMID: 19856469.
   PubMed Web of Science ®Google Scholar
• Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res. 2007;61(4):398–403. PubMed PMID: 17515861.
   PubMed Web of Science ®Google Scholar
• Hendricks MR, Lashua LP, Fischer DK, et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity Proc Natl Acad Sci U S A 2016;113(6):1642–1647. Epub 2016 Jan 06. PubMed PMID: 26729873; PMCID: 4760822. 1516979113 [pii]. DOI:10.1073/pnas.1516979113
   PubMed Web of Science ®Google Scholar
• Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis Am J Respir Crit Care Med 2007;175(9):943–950. Epub 2007 Feb 17. PubMed PMID: 17303797. 200603-343OC [pii]. DOI:10.1164/rccm.200603-343OC
   PubMed Web of Science ®Google Scholar
• Amin R, Charron M, Grinblat L, et al. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT Radiology 2012;264(3):868–875. Epub 2012 Jul 26. PubMed PMID: 22829680. radiol.12111873 [pii]. DOI:10.1148/radiol.12111873
   PubMed Web of Science ®Google Scholar
• Sodickson A. CT radiation risks coming into clearer focus. Bmj. 2013;346:f3102. Epub 2013 May 23. PubMed PMID: 23694689.
   PubMed Web of Science ®Google Scholar
• Tepper LA, Ciet P, Caudri D, et al. Validating chest MRI to detect and monitor cystic fibrosis lung disease in a pediatric cohort. Pediatr Pulmonol. 2016;51(1):34–41. Epub 2015 Oct 06. DOI:10.1002/ppul.23328
   PubMed Web of Science ®Google Scholar
• Wielputz MO, Puderbach M, Kopp-Schneider A, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med. 2014;189(8):956–965. Epub 2014 Feb 26. DOI:10.1164/rccm.201309-1659OC
   PubMed Web of Science ®Google Scholar
• Parkins MD, Rendall JC, Elborn JS Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa Chest 2012;141(2):485–493. Epub 2011 Aug 13. PubMed PMID: 21835906. chest.11-0917 [pii]. DOI:10.1378/chest.11-0917
   PubMed Web of Science ®Google Scholar
• Waters VJ, Stanojevic S, Sonneveld N, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015;14(6):755–762. Epub 2015 Feb 19. PubMed PMID: 25690407. S1569-1993(15)00009-0 [pii]. DOI:10.1016/j.jcf.2015.01.007
   PubMed Web of Science ®Google Scholar
• Van Horck M, Alonso A, Wesseling G, et al. Biomarkers in exhaled breath condensate are not predictive for pulmonary exacerbations in children with cystic fibrosis: results of a one-year observational study. PLoS One. 2016;11(4):e0152156. Epub 2016 Apr 07. DOI:10.1371/journal.pone.0152156
   Google Scholar
• Shoki AH, Mayer-Hamblett N, Wilcox PG, et al. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations Chest 2013;144(5):1659–1670. Epub 2013 Jul 23. PubMed PMID: 23868694. 1714566 [pii]. DOI:10.1378/chest.13-0693
   PubMed Web of Science ®Google Scholar
• Laguna TA, Reilly CS, Williams CB, et al. Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol. 2015;50(9):869–877. Epub 2015 Jun 27. DOI:10.1002/ppul.23225
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ Jr., Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802–808. PubMed PMID: 19729669.
   PubMed Web of Science ®Google Scholar
• Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev. 2015;(7):CD009730. Epub 2015 Aug 01. pub2. PubMed PMID: 26226131. DOI:10.1002/14651858.CD009730
   Google Scholar
• Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax. 1997;52(11):987–993. Epub 1998 Mar 06. PubMed PMID: 9487348; PMCID: 1758447.
   PubMed Web of Science ®Google Scholar
• Dalhoff A Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients Clin Microbiol Rev 2014;27(4):753–782. Epub 2014 Oct 04. PubMed PMID: 25278574; PMCID: 4187638. 27/4/753 [pii]. DOI:10.1128/CMR.00022-14
   PubMed Web of Science ®Google Scholar
• Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev. 2012;12:CD008319. pub2. PubMed PMID: 23235659. DOI:10.1002/14651858.CD008319
   Web of Science ®Google Scholar
• Hennig S, McKay K, Vidmar S, et al. Safety of inhaled (Tobi(R)) and intravenous tobramycin in young children with cystic fibrosis. J Cyst Fibros. 2014;13(4):428–434. PubMed PMID: 24565869. DOI:10.1016/j.jcf.2014.01.014
   PubMed Web of Science ®Google Scholar
• Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123(5):1495–1502. PubMed PMID: 12740266.
   PubMed Web of Science ®Google Scholar
• Yau YC, Ratjen F, Tullis E, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients J Cyst Fibros 2015;14(2):262–266. Epub 2014 Dec 03. PubMed PMID: 25453872. S1569-1993(14)00224-0 [pii]. DOI:10.1016/j.jcf.2014.09.013
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Emerson JC, McNamara S, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2011;46(2):184–192. Epub 2010 Oct 22. DOI:10.1002/ppul.21350
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 2005;366(9484):463–471. PubMed PMID: 16084254.
   PubMed Web of Science ®Google Scholar
• Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther. 2006;4(5):807–819. Epub 2006 Dec 05. DOI:10.1586/14787210.4.5.807
   PubMedGoogle Scholar
• Pettit RS, Neu N, Cies JJ, et al. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis J Antimicrob Chemother 2016;71(1):189–195. Epub 2015 Sep 30. PubMed PMID: 26416780. dkv289 [pii]. DOI:10.1093/jac/dkv289
   PubMed Web of Science ®Google Scholar
• Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573–578. PubMed PMID: 15708100.
   PubMed Web of Science ®Google Scholar
• Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes Am J Respir Crit Care Med 2010;182(9):1137–1143. Epub 2010 Jun 29. PubMed PMID: 20581166; PMCID: 3001256. 201001-0057OC [pii]. DOI:10.1164/rccm.201001-0057OC
   PubMed Web of Science ®Google Scholar
• VanDevanter DR, O’Riordan MA, Blumer JL, et al. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010;11:137. Epub 2010 Dec 12. PubMed PMID: 20925941; PMCID: 2959026. 1465-9921-11-137 [pii]. DOI:10.1186/1465-9921-11-137
   PubMed Web of Science ®Google Scholar
• Waters V, Stanojevic S, Klingel M, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2015;14(6):770–776. Epub 2015 Sep 13. PubMed PMID: 26265220. S1569-1993(15)00172-1 [pii]. DOI:10.1016/j.jcf.2015.07.010
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1–24. Epub 2011 Jan 21. rr6001a1 [pii]. PubMed PMID: 21248682.
   PubMedGoogle Scholar
• Boikos C, De Serres G, Lands LC, et al. Safety of live-attenuated influenza vaccination in cystic fibrosis Pediatrics 2014;134(4):e983–91. Epub 2014 Sep 17. PubMed PMID: 25225145. peds.2014-0887 [pii]. DOI:10.1542/peds.2014-0887
   Google Scholar
• Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 Pt 1):1447–1452. Epub 2003 Dec 05. PubMed PMID: 14654628.
   PubMed Web of Science ®Google Scholar
• Schogler A, Muster RJ, Kieninger E, et al. Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37 Eur Respir J 2016;47(2):520–530. Epub 2015 Nov 21. PubMed PMID: 26585423. 13993003.00665-2015 [pii]. DOI:10.1183/13993003.00665-2015
   PubMed Web of Science ®Google Scholar
• Vanstone MB, Egan ME, Zhang JH, et al. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2015;50(5):441–446. Epub 2015 Feb 07. DOI:10.1002/ppul.23161
   PubMed Web of Science ®Google Scholar
• Schogler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Eur Respir J 2015;45(2):428–439. Epub 2014 Nov 02. PubMed PMID: 25359346. 09031936.00102014 [pii]. DOI:10.1183/09031936.00102014.
   PubMed Web of Science ®Google Scholar
• Konstan MW, Plant BJ, Elborn JS, et al. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis. Pediatr Pulmonol. 2015;50(5):447–455. PubMed PMID: 25755212. DOI:10.1002/ppul.23173
   PubMed Web of Science ®Google Scholar
• Elborn JS, Ramsey BW, Boyle MP, et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016;4(8):617–626. 10.1016/S2213-2600(16)30121-7. PubMed PMID: 27298017.
   PubMed Web of Science ®Google Scholar
• Lucarelli M, Bruno SM, Pierandrei S, et al. A genotypic-oriented view of CFTR genetics highlights specific mutational patterns underlying clinical macrocategories of cystic fibrosis. Mol Med. 2015;21:257–275. PubMed PMID: 25910067; PMCID: PMC4503653. DOI:10.2119/molmed.2014.00229
   PubMed Web of Science ®Google Scholar
• Lucarelli M, Narzi L, Pierandrei S, et al. A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation. Genet Med. 2010;12(9):548–555. PubMed PMID: 20706124. DOI:10.1097/GIM.0b013e3181ead634
   PubMed Web of Science ®Google Scholar
• Narzi L, Ferraguti G, Stamato A, et al. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. Clin Genet. 2007;72(1):39–46. PubMed PMID: 17594398. DOI:10.1111/j.1399-0004.2007.00825.x
   PubMed Web of Science ®Google Scholar
• Narzi L, Lucarelli M, Lelli A, et al. Comparison of two different protocols of neonatal screening for cystic fibrosis. Clin Genet. 2002;62(3):245–249. PubMed PMID: 12220442.
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Sontag MK, Ren CL. Cystic Fibrosis Diagnosis and Newborn Screening. Pediatr Clin North Am. 2016;63(4):599–615. PubMed PMID: 27469178. DOI:10.1016/j.pcl.2016.04.004
   PubMed Web of Science ®Google Scholar
• Brennan ML, Schrijver I. Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. J Mol Diagn. 2016;18(1):3–14. PubMed PMID: 26631874. DOI:10.1016/j.jmoldx.2015.06.010
   PubMed Web of Science ®Google Scholar
• Carter SC, McKone EF. Pharmacogenetics of cystic fibrosis treatment. Pharmacogenomics. 2016;17(13):1453–1463. PubMed PMID: 27490265. DOI:10.2217/pgs.16.25
   PubMed Web of Science ®Google Scholar